In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of FibroGen Inc (NASDAQ: FGEN) closed at $0.60 in the last session, up 7.93% from day before closing price of $0.55. In other words, the price has increased by $7.93 from its previous closing price. On the day, 0.76 million shares were traded. FGEN stock price reached its highest trading level at $0.61 during the session, while it also had its lowest trading level at $0.5302.
Ratios:
We take a closer look at FGEN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 08, 2023, Downgraded its rating to Underperform and sets its target price to $2 from $4 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 12 ’24 when Adib Deyaa bought 22,123 shares for $1.17 per share. The transaction valued at 25,884 led to the insider holds 82,123 shares of the business.
Wettig Thane bought 50,000 shares of FGEN for $95,470 on Mar 07 ’24. The CEO now owns 470,178 shares after completing the transaction at $1.91 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FGEN now has a Market Capitalization of 60351156 and an Enterprise Value of 103849944. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.34. Its current Enterprise Value per Revenue stands at 0.597 whereas that against EBITDA is -0.626.
Stock Price History:
The Beta on a monthly basis for FGEN is 0.75, which has changed by -0.3018868 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, FGEN has reached a high of $2.93, while it has fallen to a 52-week low of $0.18. The 50-Day Moving Average of the stock is 41.56%, while the 200-Day Moving Average is calculated to be -17.76%.
Shares Statistics:
According to the various share statistics, FGEN traded on average about 1.44M shares per day over the past 3-months and 1819320 shares per day over the past 10 days. A total of 100.77M shares are outstanding, with a floating share count of 93.69M. Insiders hold about 7.02% of the company’s shares, while institutions hold 45.46% stake in the company. Shares short for FGEN as of 1730332800 were 4324077 with a Short Ratio of 2.12, compared to 1727654400 on 4544637. Therefore, it implies a Short% of Shares Outstanding of 4324077 and a Short% of Float of 5.07.
Earnings Estimates
The stock of FibroGen Inc (FGEN) is currently drawing attention from 1.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.86 and -$0.86 for the fiscal current year, implying an average EPS of -$0.86. EPS for the following year is -$0.38, with 1.0 analysts recommending between -$0.38 and -$0.38.
Revenue Estimates
According to 2 analysts, the current quarter’s revenue is expected to be $24.91M. It ranges from a high estimate of $25.82M to a low estimate of $24M. As of the current estimate, FibroGen Inc’s year-ago sales were $27.14M
A total of 2 analysts have provided revenue estimates for FGEN’s current fiscal year. The highest revenue estimate was $178.7M, while the lowest revenue estimate was $177M, resulting in an average revenue estimate of $177.85M. In the same quarter a year ago, actual revenue was $147.75MBased on 2 analysts’ estimates, the company’s revenue will be $166.15M in the next fiscal year. The high estimate is $187.3M and the low estimate is $145M.
